Quick Answer
Xenon Pharmaceuticals Inc. reported Total Assets of $633.16 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -20.7% in Total Assets from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $54.14 million | Q1 2015: $79.40 million | Q2 2015: $76.53 million | Q3 2015: $69.94 million | Q1 2016: $61.15 million | Q2 2016: $55.69 million | Q3 2016: $73.37 million | Q1 2017: $60.79 million | Q2 2017: $54.23 million | Q3 2017: $46.36 million | Q1 2018: $37.76 million | Q2 2018: $65.44 million | Q3 2018: $130.46 million | Q1 2019: $114.55 million | Q2 2019: $105.89 million | Q3 2019: $98.90 million | Q2 2020: $210.68 million | Q3 2020: $199.13 million | Q1 2021: $290.67 million | Q2 2021: $274.71 million | Q3 2021: $264.35 million | Q1 2022: $558.06 million | Q2 2022: $807.38 million | Q3 2022: $775.81 million | Q1 2023: $719.87 million | Q2 2023: $684.90 million | Q3 2023: $671.09 million | Q1 2024: $919.02 million | Q2 2024: $884.01 million | Q3 2024: $835.90 million | Q1 2025: $743.28 million | Q2 2025: $674.28 million | Q3 2025: $607.84 million.
- Over the full 13 years of available data (2013 to 2025), Xenon Pharmaceuticals Inc.'s Total Assets has grown by 1,062.0%.
- Historical annual values: Fiscal year 2025: $633.16 million | Fiscal year 2024: $798.14 million | Fiscal year 2023: $964.80 million | Fiscal year 2022: $754.15 million | Fiscal year 2021: $572.01 million | Fiscal year 2020: $189.19 million | Fiscal year 2019: $147.70 million | Fiscal year 2018: $122.43 million | Fiscal year 2017: $46.12 million | Fiscal year 2016: $67.49 million | Fiscal year 2015: $63.95 million | Fiscal year 2014: $87.42 million | Fiscal year 2013: $54.49 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: